Mitoxantrone
- Generic Name
- Mitoxantrone
- Drug Type
- Small Molecule
- Chemical Formula
- C22H28N4O6
- CAS Number
- 65271-80-9
- Unique Ingredient Identifier
- BZ114NVM5P
- Background
An anthracenedione-derived antineoplastic agent.
- Indication
For the treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Promyelocytic Leukemia, Hodgkin's Lymphoma, Metastatic Breast Cancer, Non-Hodgkin's Lymphoma (NHL), Progressive Relapsing Multiple Sclerosis, Relapsed Leukemia, Relapsed Lymphomas, Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Hormone refractory, advanced Prostate cancer, Relapsed Hepatocellular carcinoma
- Associated Therapies
- Autologous hematopoietic stem cell transplant
Combination Chemotherapy in Treating Patients With Lymphoma
- Conditions
- Lymphoma
- Interventions
- Biological: Filgrastim (G-CSF)Biological: Bleomycin Sulfate (BLM)Biological: Recombinant Interferon AlfaProcedure: Peripheral Blood Stem Cell TransplantationRadiation: Radiation Therapy
- First Posted Date
- 2003-04-16
- Last Posted Date
- 2018-11-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 116
- Registration Number
- NCT00002835
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Promyelocytic Leukemia
- Conditions
- Leukemia
- First Posted Date
- 2003-04-11
- Last Posted Date
- 2013-09-20
- Target Recruit Count
- 750
- Registration Number
- NCT00002701
- Locations
- 🇧🇪
Universitair Ziekenhuis Antwerpen, Edegem, Belgium
🇮🇹Federico II University Medical School, Naples (Napoli), Italy
🇮🇹Ospedale S. Gennora USL 42, Naples (Napoli), Italy
Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia
- Conditions
- LeukemiaNeutropenia
- First Posted Date
- 2003-04-10
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- Medical Research Council
- Target Recruit Count
- 2000
- Registration Number
- NCT00002658
- Locations
- 🇬🇧
University of Wales College of Medicine, Cardiff, Wales, United Kingdom
Ixabepilone Compared With Mitoxantrone and Prednisone in Treating Patients With Refractory Metastatic Prostate Cancer
- Conditions
- Stage IV Prostate CancerAdenocarcinoma of the ProstateRecurrent Prostate Cancer
- Interventions
- First Posted Date
- 2003-04-09
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 80
- Registration Number
- NCT00058084
- Locations
- 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
Combination Chemotherapy Followed By Filgrastim or Sargramostim in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
- Conditions
- Leukemia
- First Posted Date
- 2003-01-28
- Last Posted Date
- 2011-03-08
- Lead Sponsor
- Roswell Park Cancer Institute
- Registration Number
- NCT00053131
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Bevacizumab, Cytarabine, and Mitoxantrone on Treating Patients With Hematologic Cancers
- Conditions
- Myelodysplastic SyndromesLeukemia
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2019-10-17
- Lead Sponsor
- University of Maryland, Baltimore
- Registration Number
- NCT00015951
- Locations
- 🇺🇸
Marlene and Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States
🇺🇸Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States
Filgrastim Compared With Sargramostim Plus Chemotherapy, Peripheral Stem Cell Transplantation, and Interferon Alfa in Treating Patients With Multiple Myeloma
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 87
- Registration Number
- NCT00005987
- Locations
- 🇺🇸
University of Minnesota Cancer Center, Minneapolis, Minnesota, United States
S9916, Combination Therapy in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-02-25
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 770
- Registration Number
- NCT00004001
- Locations
- 🇺🇸
CCOP - Cedar Rapids Oncology Project, Cedar Rapids, Iowa, United States
🇺🇸Mayo Clinic, Jacksonville, Florida, United States
🇺🇸CCOP - Iowa Oncology Research Association, Des Moines, Iowa, United States
Monoclonal Antibody Plus Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes
- Conditions
- LeukemiaMyelodysplastic Syndromes
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-02-20
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 47
- Registration Number
- NCT00028899
- Locations
- 🇺🇸
Emory University Hospital - Atlanta, Atlanta, Georgia, United States
🇺🇸CancerCare of Maine at Eastern Maine Medial Center, Bangor, Maine, United States
🇺🇸Alvin and Lois Lapidus Cancer Institute at Sinai Hospital, Baltimore, Maryland, United States
S9921, Hormone Therapy With or Without Mitoxantrone and Prednisone in Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2022-12-30
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 983
- Registration Number
- NCT00004124
- Locations
- 🇺🇸
Cancer Care Center at Advocate Lutheran Hospital, Park Ridge, Illinois, United States
🇺🇸Alta Bates Comprehensive Cancer Center, Berkeley, California, United States
🇺🇸Bismarck Cancer Center, Bismarck, North Dakota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.